NanoVibronix (NASDAQ: NAOV) is one of 28 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it compare to its competitors? We will compare NanoVibronix to similar companies based on the strength of its valuation, dividends, institutional ownership, earnings, risk, profitability and analyst recommendations.
This is a breakdown of current ratings and price targets for NanoVibronix and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares NanoVibronix and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares NanoVibronix and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|NanoVibronix Competitors||$1.35 billion||$134.43 million||17.38|
NanoVibronix’s competitors have higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
14.2% of NanoVibronix shares are owned by institutional investors. Comparatively, 58.3% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 18.7% of NanoVibronix shares are owned by company insiders. Comparatively, 9.5% of shares of all “Surgical appliances & supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
NanoVibronix has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500. Comparatively, NanoVibronix’s competitors have a beta of 1.14, suggesting that their average share price is 14% more volatile than the S&P 500.
NanoVibronix competitors beat NanoVibronix on 9 of the 13 factors compared.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.
Receive News & Ratings for NanoVibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoVibronix and related companies with MarketBeat.com's FREE daily email newsletter.